摘要
目的探讨神经生长因子对重型颅脑损伤患者血清神经元特异性烯醇化酶(NSE)和超敏C反应蛋白(hsCRP)水平的影响及疗效观察。方法选择68例重型颅脑损伤患者,随机分为观察组和对照组。两组患者均予以常规内科治疗(保持呼吸道通畅、降低颅内压、止血、维持水电质平衡及营养支持等),有手术指征的及时手术治疗。治疗组在此治疗的基础上加用神经生长因子18μg皮下注射,每日1次,疗程2周。观察两组治疗后的效果及药物不良反应,并比较治疗前后血清NSE和hs-CRP水平的变化。结果治疗2周后,观察组和对照组患者格拉斯哥昏迷评分[(12.45±1.81)、(10.48±1.37)分]均较治疗前[(7.52±1.34)、(7.49±1.38)分]明显改善(P<0.01或P<0.05),观察组的改善幅度大于对照组(P<0.05);两组患者血清NSE和hs-CRP水平[(18.76±4.68)μg/L、(28.56±6.71)μg/L、(11.68±3.67)mg/L、(17.58±4.11)mg/L]均较治疗前[(35.89±7.52)μg/L、(35.94±8.01)μg/L、(25.64±5.34)mg/L、(25.19±5.62)mg/L]明显下降(P<0.05或P<0.01),观察组下降幅度大于对照组(P<0.05)。两组患者药物不良反应发生率比较差异无统计学意义(χ2=0.18,P>0.05)。结论神经生长因子治疗重型颅脑损伤患者能有效地提高治疗效果,具有良好的脑保护作用,其作用机制与降低血清NSE和hs-CRP水平密切相关。
Objective To discuss influence and curative effect observation of nerve growth factor（NGF） on serum neuronspecific enolase（NSE） and high-sensitivity C-reactive protein（hs-CRP） levels of patients with severe traumatic brain injury. Methods 68 cases of patients with severe traumatic brain injury were selected and divided into observation group and control group at random. The patients in two groups were given routine medical treatment（maintenance of airway open, decreasing intracranial pressure, hemostasis, maintenance of water-electrolyte balance, nutrition supporting and other medical treatment） and timely surgical treatment on patients with surgical indications. The patients in treatment group were additionally 18 μg NGF by hypodermic injection, once for daily, with 2 weeks＇ course of treatment.The curative effect and drug adverse reaction（DAR） of patients in two groups after the medical treatment were observed, and the changes of serum NSE and hs-CRP levels before and after medical treatment were compared as well.Results After 2 weeks＇ treatment, the GCS scores of patients in two groups [（12.45±1.81）,（10.48±1.37） scores] were improved than before [（7.52±1.34）,（7.49±1.38） scores]（P 〈0.01 or P 〈0.05）, and the improvement rate of patients in observation group was much higher than that in control group（P 〈0.05）. The serum NSE and hs-CRP of patients in twogroups [（18.76 ±4.68） μg/L,（28.56 ±6.71） μg/L,（11.68 ±3.67） mg/L,（17.58±4.11） mg/L] obviously declined than before [（35.89 ±7.52） μg/L,（35.94 ±8.01） μg/L,（25.64 ±5.34） mg/L,（25.19 ±5.62） mg/L]（P 〈0.05 or P 〈0.01）,and the declining rate of patients in observation group was higher than that in control group（P 〈0.05）. After comparing the occurrence rates of DAR of patients in two groups, no statistical differences appeared（χ2=0.18, P 〉0.05）. Conclusion The application of NGF on patients with severe traumatic brain injury can effectively improve treatment effect, and has favorable protection effect on brain, whose mechanism of action has close effect on reducing serum NSE and hs-CRP levels.
出处
《中国医药导报》
CAS
2015年第3期107-109,113,共4页
China Medical Herald
基金
浙江省医药卫生科技计划项目(编号2014KYB246)
关键词
重型颅脑损伤
神经生长因子
血清特异性烯醇化酶
超敏C反应蛋白
Severe traumatic brain injury
Nerve growth factor
Serum neuron-specific enolase
High-sensitivity C-reactive protein
